Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas

Emmanuel T. Akporiaye, Deborah Bradley-Dunlop, Sandra J. Gendler, Pinku Mukherjee, Cathy S. Madsen, Tobias Hahn, David G. Besselsen, Sharon M. Dial, Haiyan Cui, Katrina Trevor

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/MIN/+ (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-γ secretion by lymphocytes.

Original languageEnglish (US)
Pages (from-to)6965-6974
Number of pages10
JournalVaccine
Volume25
Issue number39-40
DOIs
StatePublished - Sep 28 2007

    Fingerprint

Keywords

  • Adenoma
  • Immunotherapy
  • MUC1.Tg/MIN mice

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Akporiaye, E. T., Bradley-Dunlop, D., Gendler, S. J., Mukherjee, P., Madsen, C. S., Hahn, T., Besselsen, D. G., Dial, S. M., Cui, H., & Trevor, K. (2007). Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine, 25(39-40), 6965-6974. https://doi.org/10.1016/j.vaccine.2007.06.063